Sarep­ta Ther­a­peu­tics said it won't com­ply with an FDA re­quest to stop ship­ping the com­pa­ny's treat­ment for Duchenne mus­cu­lar dy­s­tro­phy, fol­low­ing two pa­tient deaths, like­ly set­ting up a high-pro­file bat­tle with the agency over the con­tro­ver­sial gene ther­a­py...